No drug targets autism’s core symptoms, but medications from antipsychotics to leucovorin can address irritability, sleep, attention, and other co-occurring challenges.
Xavier Amador explains how the LEAP communication strategy helps clinicians build trust with patients whose anosognosia makes them unable to recognize their own illness.
A placebo-controlled trial finds mirtazapine modestly improves sleep in older adults, but daytime drowsiness and confusion caused dropout in a notable minority of patients.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747)
-_-Benefits-Side-Effects-and-Review-of-Trials_Thumb.webp?t=1727890706)
